Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to -$800000.0.

  • Myriad Genetics' Change in Account Payables rose 7777.78% to -$800000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 180000.0%. This contributed to the annual value of $4.7 million for FY2024, which is 22702.7% up from last year.
  • According to the latest figures from Q3 2025, Myriad Genetics' Change in Account Payables is -$800000.0, which was up 7777.78% from $3.6 million recorded in Q2 2025.
  • Myriad Genetics' Change in Account Payables' 5-year high stood at $14.0 million during Q4 2021, with a 5-year trough of -$12.9 million in Q3 2021.
  • Its 5-year average for Change in Account Payables is $527777.8, with a median of -$250000.0 in 2021.
  • In the last 5 years, Myriad Genetics' Change in Account Payables soared by 126666.67% in 2021 and then plummeted by 116666.67% in 2022.
  • Myriad Genetics' Change in Account Payables (Quarter) stood at $14.0 million in 2021, then crashed by 117.14% to -$2.4 million in 2022, then plummeted by 145.83% to -$5.9 million in 2023, then soared by 81.36% to -$1.1 million in 2024, then rose by 27.27% to -$800000.0 in 2025.
  • Its Change in Account Payables was -$800000.0 in Q3 2025, compared to $3.6 million in Q2 2025 and -$1.1 million in Q4 2024.